New research highlights the complex role of mitochondrial impairment in diabetic kidney disease, revealing diverse molecular patterns and promising therapeutic avenues, including natural compounds and targeted drugs, with a call for more clinical studies.
Researchers say mitochondrial failure sits at the centre of diabetic kidney disease, helping to explain why current treatment can slow, but not stop, damage to the kidneys. A review in Dove Press’s peer-reviewed journal summarises evidence that excess glucose and fatty acids disrupt energy production in kidney cells, driving oxidative stress, inflammation, fibrosis and, eventually, loss of renal function.
The review argues that the field has moved beyond viewing mitochondrial injury as a single defect. Instead, it describes a wider network of problems involving impaired mitophagy, altered mitochondrial shape and movement, reduced fatty-acid burning, and changes in how kidney cells use fuel. In proximal tubular cells, which have high energy demands, these shifts can push metabolism away from fatty-acid oxidation and towards less efficient glycolysis, worsening injury over time.
A major theme is the value of multi-omics, an approach that combines data from genes, RNA, proteins, metabolites and tissue maps. The review says spatial transcriptomics, proteomics and metabolomics have begun to show that mitochondrial damage is not uniform across the kidney. Injured proximal tubular cells, podocytes and sclerotic glomeruli each appear to follow distinct molecular patterns, with some areas showing stronger inflammatory signalling and others showing deeper metabolic failure.
The review also links mitochondrial dysfunction to broader disease pathways, including the renin-angiotensin-aldosterone system and the gut–kidney axis. It notes that microbiome-derived metabolites can either worsen or ease kidney injury, while harmful compounds such as phenyl sulfate and imidazolepropionic acid appear to impair mitochondrial function. At the same time, beneficial short-chain fatty acids may support mitochondrial health and damp inflammation.
On treatment, the review says established diabetes and kidney drugs may work in part by restoring mitochondrial homeostasis. It points to evidence that ACE inhibitors, angiotensin receptor blockers, SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists can improve mitochondrial quality control, reduce oxidative stress and support fatty-acid oxidation. The review also highlights growing interest in natural compounds such as astragaloside IV, berberine, arctigenin and poricoic acid A, which experimental studies suggest may protect kidney cells by acting on mitochondrial pathways.
The authors say the main challenge now is turning these molecular insights into clinical use. They call for longitudinal human studies, better validation in cell-specific models and stronger integration of spatial and single-cell data. Their conclusion is that mitochondrial dysfunction is not just a feature of diabetic kidney disease, but a promising target for earlier diagnosis and more precise treatment.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
